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On 6th June 2001, Julie Denekamp died, aged 58, after a 2 year
struggle with inflammatory breast cancer. After her diagnosis,
Julie and her husband Bo Littbrand remained at their home 
in Sweden, where Julie continued to supervise and direct her
Translational Research Group at Umea University. She was still
correcting manuscripts for her students (with that famous red pen)
until one week before her death! Julie and Bo also tried to spend as
much time as possible at their second home in Cornwall, England.
They were en route to Cornwall, visiting Julie’s mother in
Cwmbran, Wales, when Julie died after having a happy and
peaceful few days with her family. Unfortunately, she never saw
her first grandchild, Cèire Julianne, who was born a few days later
to her daughter Liz and Stephen Fowley.
Julie was truly one of the driving forces in the radiobiology
community. She made a big impression on all who met her, with
her spirited and enthusiastic approach to both her professional and
personal life. One of Julie’s hallmarks was her love of a good
debate. Since Julie was blessed with an exceptionally sharp mind
and superb didactic skills, this meant that she had often won the
debate before the rest of us had sorted out what the main issues
were! Participating in scientific discussions with Julie was an
exhilarating and educational experience and several generations of
radiobiologists, both older and younger than she, have benefited
enormously from her insight, knowledge and encouragement.
Another hallmark was her courage and integrity. Julie would fight
tirelessly to search out a scientific truth or to defend a moral prin-
ciple or person in whom she believed. She was always committed to
the truth, no matter if this went against accepted dogma. This some-
times made her own life difficult and led to conflicts with the estab-
lishment but she never took the easy way out.
Julie graduated with a first class honours degree in zoology and
botany from London University in 1964. She was then appointed
by Jack Fowler to work as his research assistant at the MRC
Postgraduate School, Hammersmith Hospital, London. In addition
to the work Julie did with Jack, on fractionation effects of radia-
tion in normal tissues and tumours, Julie began her own research
on tumour cell kinetics. This resulted in her PhD thesis in 1968.
After completing her thesis, Julie went with her first husband, Stan
Field, and baby daughter Caroline to Stanford, for a 1 year post-
doctoral period. Shortly after returning to London, their second
child, Elizabeth, was born. In 1971 Julie moved with Jack Fowler,
Adrian Begg, Peter Sheldon and Susan Harris from Hammersmith
to the Gray Laboratory, where Jack was appointed as Director.
By the time I became Julie’s research assistant, in the summer of
1973, she already had a reputation as an excellent experimental
scientist and her lecturing and debating skills were legendary. Julie
could initially seem somewhat intimidating, with her direct and
sometimes confrontational approach to scientific discussions.
How many of us have experienced that quizzical raised left
eyebrow which seemed to say ‘are you absolutely sure about 
that’? However, it soon became apparent that Julie took great
delight in discussing and analysing scientific results and that she
was only interested in looking critically at the data, not the experi-
menter or discussant. Julie was, in fact, an inspirational teacher
and mentor. She had an enviable ability to assess and assimilate
data and to present them in a clear and logical fashion. She also
managed to instil enthusiasm and excitement into her team and
was always loyal and supportive. Cancer research was more than a
job to Julie; it was a passion.
Julie worked at the Gray Lab for almost 25 years. In 1977 she
was made Head of the Radiobiology Applied to Therapy Section,
and in 1988 she was appointed as the Institute Director, succeeding
Jack Fowler. During this period she made many seminal contribu-
tions in the field of oncology and in 1980 she was awarded the
prestigious DSc degree. Some of her most significant contribu-
tions include her work on time factors and compensatory prolifer-
ation after fractionated radiotherapy, modifiers of the radiation
response to exploit differences between tumours and normal
tissues, e.g. hyperfractionation, radiosensitisers, radioprotectors
and hyperthermia, and her pioneering work on targeting the
tumour vasculature as a novel form of cancer treatment. It was
Julie who showed that the proliferation rate of endothelial cells in
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moment she had observed this difference, in the early 1980s, Julie
realised that this represented an opportunity for specific tumour
targeting and she redirected a large part of her research programme
to this end. Over the last few years, vascular targeting has become
widely recognised as one of the most promising new approaches
for cancer therapy. Other examples where Julie was instrumental
in initiating new clinical protocols based on results from the labo-
ratory (true ‘translational research’) are the accelerated, hyperfrac-
tionated, radiotherapy schedule CHART and, more recently, the 
ARCON trials, which combine accelerated radiotherapy to over-
come tumour proliferation, with carbogen and nicotinamide to
overcome tumour hypoxia.
In addition to her scientific achievements at the Gray Lab, Julie
was responsible for initiating numerous building, refurbishing and
upgrading projects. These included conversion of the derelict Art
Nouveau hospital chapel into the present-day, stylish Fowler Scott
Library. Since the funds available for this conversion were limited,
Julie motivated the entire lab to ‘volunteer’ to do much of the
refurbishing themselves. It was typical of Julie that she imbued her
own, personal style on such a project and motivated an entire team
to willingly give their time to achieve the goal. I’m sure that this
will strike a chord with the many visiting workers who passed
through the Gray Lab while Julie was there. They will all have
experienced her infectious enthusiasm and generosity, both in
scientific exchanges and on a personal level.
By the end of the 1980s Julie had a new love in her life, Bo
Littbrand, who was then the Dean and Head of Radiotherapy at
Umea University in Sweden. Julie and Bo were married in June
1989 and many of her friends and colleagues were privileged to
share their happiness on that beautiful summer’s day. For 5 years
after their marriage. Julie continued as Director of the Gray Lab,
but increasing struggles with CRC Head Office over funding,
organisational structure and future directions took their toll. In
1994 Julie left the Gray Lab and moved to Sweden so that she and
Bo could spend more time together. No doubt Julie also thought
she would be free of administrative hassle and fights over
resources!
In 1995 Julie was appointed as Professor of Radiobiology in
the Oncology Department at Umea University. Together with Bo,
she built up a new Translational Research Group, with a mixture
of clinicians, physicists and biologists. This period of Julie’s life
was also very productive, despite ill health and recurring
conflicts with established groups within the university over
space and resource allocations. During her time in Umea, Julie
and her group focused on analyses of clinical data, on long-term
morbidity after radiotherapy for breast cancer, proliferation
patterns in colorectal cancer, and on modelling the impact of
tumour hypoxia on treatment. Julie was particularly excited
about the possibility of exploiting chronic tumour hypoxia for
radiosensitisation, if these metabolically starved cells become
repair incompetent. This is yet another example of how Julie was
always  prepared to challenge established dogma and look at
experimental data in a new light.
In addition to her research activities in Umea, Julie was very
active in organising teaching courses, workshops and conferences.
In all of these activities Julie’s personal style and flair was
apparent. Not only were the courses of a high scientific and educa-
tional value, they also introduced the participants to local Swedish
culture, cuisine and nature. Julie made sure that the intensive scien-
tific programme was balanced by an excellent social programme
with picnics at local beauty spots. She and Bo would also entertain
course participants and lecturers at their own home in Innertavle.
These are some of the reasons that Julie has had such a big
impact on the lives of all who knew her and worked with her. Julie
will be missed for her warmth, humour and lively friendship, as
much as for her very considerable scientific contributions to the
field. Julie was special, and she will continue to be remembered
with affection and respect for many years to come.
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